Ztalmy (ganaxolone) received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for the treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD), a genetic disorder defined by seizures beginning in infancy.

If approved, ganaxolone will be the first treatment in ...